US Pharma MarketingThiel-backed Lindus pivots to hunting external drug assets after CRO-arm sale
Lindus Therapeutics sheds its CRO business, rebrands from Lindus Health and pivots to in-licensing external drug assets, CEO Meri Beckwith says. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
A Peter Thiel-backed transatlantic startup that once branded itself as an “anti-CRO” is pivoting from a clinical trials operator to a drug developer.
Lindus Therapeutics is betting that its experience over ...
Source: Endpoints News